Yao Zhu
@yao_zhu_sh
Followers
566
Following
17K
Media
72
Statuses
2K
(5/6) Most exciting part is this novel MOA has very encouraging prelim activity against mCRPC. In pts with ≥ 6 wks tx, PSA50 was 59%, PSA90 was 32%, PR in 5/5 pts with RECIST-evaluable, and activity regardless prior tx or genomic alterations
2
5
9
Congratulations to the legend, Dr. Maha Hussain, on receiving the @PCFnews Lifetime Achievement Award at #PCFRetreat25 👏 From groundbreaking drug approvals in #prostatecancer to an extraordinary legacy of mentorship—so fortunate to call you my mentor.@UroToday @PCF_Science
1
20
80
Agree my friend @MonikaJoshimd huge effort to open EA8231 phase 3 trial with SG/pembro vs salvage chemo in advanced urothelial Ca! Welcome everyone to open it at your site! It builds upon our +ve phase 2 trial: https://t.co/ruNK19wb4y
@SuzanneColeMD @KMittalmd @OncoAlert @eaonc
@eaonc @PGrivasMDPhD Thrilled to see this come through- @PGrivasMDPhD An important step for evaluating IO rechallenge as the current landscape is changing in UCC. Our thx to @eaonc Noah Hahn Naomi Hass, @KMittalmd, Melissa Reimers, Alicia Morgan, Libby Wulff, @SuzanneColeMD. Pls Consider opening it
1
5
16
#EMBARK didn’t write the book📕on #BCR📈#ProstateCancer-it is merely the first chapter What do #BCR trials look like in the #PSMA🩻era? 30+experts met @theNCI🏛️ to provide a roadmap🧭 @JCO_ASCO @ASCO @PCF_Science @APCCC_Lugano @urotoday
https://t.co/ePbf8j7KQU
ascopubs.org
PURPOSEBiochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasens...
1
19
46
5/ Clinically, patients with the highest post-SBRT AREG & CD14⁺CD33⁺pEGFR⁺ monocytes had worse outcomes (COSINR trial). ⚠️ Implication: dose matters — incomplete local control can trigger systemic effects.
1
1
5
🚨 In this episode Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. 🎙️ GU Oncology Now: https://t.co/tq6ij4QLoO 🍎 Apple Podcasts: https://t.co/tq6ij4QLoO 🎧Spotify: https://t.co/Zm9En8bbMK
0
10
13
What changes do we see in the TME post IO? Does it differ between responders and nonresponders?Tumor reactive phenotypes, and not quantity, of T cells enriched in responders as observed in bulk RNAseq, imaging mass cytometry and single cell RNAseq.
1
1
12
Phenomenal discussion by @AndreaNecchi on DV -tori in HER2+ mUC! @myESMO Masterful synthesis from disease biology to therapeutic relevance in #EVPembro era. "Polarization of cancer care" this can bridge global disparities in access to novel tx. @DrChoueiri @montypal @myESMO
0
6
19
4/4 Do these data tell us if we can stop ongoing perioperative immune therapy (NIAGARA KN905)? Sadly not. Other randomised trials will be needed to address this. ctDNA analysis data from NIAGARA is below. All of these data were with the informed signitera assay #ESMO25
0
15
35
The countdown for radical cystectomy being an obsolete surgery is on.....5 years? 🧐🧐
6
13
82
A new study suggests iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, with a manageable safety profile. https://t.co/u3ZwIyn5HE
#ESMO25
thelancet.com
Iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, with a manageable safety profile. These...
2
11
33
Learned so much from this #ESMO25 overview of existing ADCs in #bladdercancer by @AndreaNecchi in a session hosted @Silke_Gillessen & @drenriquegrande. The sheer number of trials examining ADCs in #bladdercancer is mind-boggling, incl multiple phase 3s.
1
14
39
While I always want better outcomes for patients, have written and spoke on this topic endlessly. Sadly add this to the list of things I warned ppl of in PCa (PARPi in non-BRCA, WPRT, brachy boost, focal, protons, ARPI in localized dz). STAMPEDEs results are a subgroup analysis
#ESMO25 Highly anticipated results of ENZARAD The results speak for themselves but I think this is something @DrSpratticus has been harping about for blanket ARSI for high risk #ProstateCancer patients
7
21
87
Such a great day. Two Trop2 ADCs (SG, Dato-DXd) just replaced 1L chemo for IO-ineligible mTNBC — a huge unmet need. Pros and cons for the choice of each. Dato-DXd, though, looked safer, with no G5 toxicity (vs 7 deaths with SG). Proactive management of ADC toxicities is key.
4
19
86
Tdxd alone was not effective as NACT . I am surprised. Are u ? #destinybreast11 @dr_yakupergun @ErikaHamilton9 @myESMO
0
3
6
What an incredible ESMO meeting! It was wonderful to experience such amazing science and catch up with so many friends. Together, we are making progress in the fight to improve survival for our patients in oncology.#ESMO25
0
3
9
A state-of-the-art session by @tompowles1 , he truly put his heart into it. From EV+pembro transforming urothelial cancer, to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer, NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO
1
16
41
So much food for thought in @tompowles1’s lecture on ADC combos A few key points: - synergy is rare, but additive is often transformative - activity of combos is tumor-specific - the ADC target matters. The payload matters. The linker matters - innovation in biomarkers is needed
A state-of-the-art session by @tompowles1 , he truly put his heart into it. From EV+pembro transforming urothelial cancer, to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer, NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO
1
14
46